Filed Pursuant to Rule 424(b)(5)
Registration No. 333-264984-01
The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED NOVEMBER 7, 2023
PRELIMINARY PROSPECTUS SUPPLEMENT
(To Prospectus Dated May 16, 2022)
$260,000,000
IDACORP, Inc.
Common Stock
The forward counterparty below is offering $260,000,000 of shares of our common stock. We expect to enter into a forward sale agreement with Morgan Stanley & Co. LLC, which we refer to as the forward counterparty, with respect to $260,000,000 of shares of our common stock. In connection with the forward sale agreement, the forward counterparty or its affiliates are borrowing from third parties and selling to the underwriters an aggregate of $260,000,000 of shares of our common stock that will be delivered in this offering. If in the good faith, commercially reasonable judgment of the forward counterparty, it or its affiliate is unable to borrow and deliver for sale on the anticipated closing date a number of shares of our common stock underlying the forward sale agreement, or it or its affiliate would be unable to borrow, at a stock loan rate not greater than a specified rate, and deliver for sale on the anticipated closing date such number of shares of our common stock, or if certain other conditions to the forward counterparty’s obligations have not been satisfied, then we will issue and sell directly to the underwriters a number of shares of our common stock equal to the number of shares that the forward counterparty does not borrow and deliver.
We will not initially receive any proceeds from the sale of our common stock sold by the forward counterparty to the underwriters, except in certain circumstances described in this prospectus supplement, including the last sentence of the previous paragraph. The forward sale agreement provides for settlement on a settlement date or dates to be specified at our discretion no later than the date that is 12 months from entry into the forward sale agreement. We may settle the forward sale agreement entirely by the full physical delivery of shares of our common stock in exchange for cash proceeds, or we may elect cash settlement or net share settlement for all or a portion of our obligations under the forward sale agreement. If we elect to cash settle all or a portion of the forward sale agreement, we may not receive any proceeds from such election, and we may owe cash to the forward counterparty. If we elect to net share settle all or a portion of the forward sale agreement, we will not receive any cash proceeds from such election, and we may owe shares of our common stock to the forward counterparty. See “Underwriting (Conflicts of Interest)—Forward Sale Agreement” for a description of the forward sale agreement. We expect to use net proceeds from settlement of the forward sale agreement, if any, for general corporate purposes, which may include capital expenditures. See “Use of Proceeds.”
Our common stock is listed on the New York Stock Exchange (the “NYSE”) under the symbol “IDA.” The last reported sale price of our common stock on the NYSE on November 6, 2023 was $98.21 per share.
Investing in our common stock involves risks. See “Risk Factors” beginning on page S-6 of this prospectus supplement to read important factors you should consider before investing in our common stock.
The underwriters propose to offer shares of our common stock from time to time for sale in one or more transactions on the NYSE, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices, subject to receipt and acceptance by the underwriters and subject to their right to reject any order in whole or in part. In connection with the sale of shares of our common stock, the underwriters may be deemed to have received compensation in the form of underwriting discounts. The underwriters may effect such transactions by selling shares of our common stock to or through dealers, and such dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or purchasers of shares of our common stock for whom they may act as an agent or to whom they may sell as principal. The difference between the price at which the underwriters purchase shares of our common stock and the price at which the underwriters resell such shares may be deemed underwriting compensation.
The underwriters have agreed to purchase shares of our common stock from the forward counterparty at a price of $ per share. We expect to receive estimated net proceeds from the sale of shares of our common stock, before expenses, of approximately $ (or approximately $ if the underwriters’ option to purchase additional shares of our common stock is exercised in full, and we elect to have the forward counterparty or its affiliate borrow and deliver such shares to the underwriters as described in detail below) upon full physical settlement of the forward sale agreement, which we expect to occur no later than the date that is 12 months from entry into the forward sale agreement. For the purpose of calculating the estimated net proceeds to us, we have assumed that the forward sale agreement is fully physically settled based on the initial forward sale price of $ per share. The forward sale price is subject to adjustment pursuant to the forward sale agreement, and the actual proceeds, if any, will be calculated as described in this prospectus supplement.
We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase up to an additional $39,000,000 of shares of our common stock at a price of $ per share, subject to certain possible adjustments. If such option is exercised, we may, in our sole discretion, enter into an additional forward sale agreement with the forward counterparty in respect of the number of shares that are subject to the exercise of such option. Unless the context requires otherwise, the term “forward sale agreement” as used in this prospectus supplement includes any additional forward sale agreement that we may enter into with the forward counterparty in connection with the exercise, by the underwriters, of their option to purchase additional shares. If such option is exercised and we elect not to enter into an additional forward sale agreement, we have agreed to issue and sell directly to the underwriters the number of shares of our common stock that are subject to the exercise of such option. If we enter into an additional forward sale agreement, and if in the good faith, commercially reasonable judgment of the forward counterparty, it or its affiliate is unable to borrow, or is unable to borrow at a stock loan rate not greater than a specified amount, and deliver for sale on the anticipated closing date for the exercise of such option, such amount of shares of our common stock underlying the additional forward sale agreement, or if certain other conditions to the forward counterparty’s obligations have not been satisfied, then we will issue and sell directly to the underwriters a number of shares of our common stock equal to the number of shares of our common stock that the forward counterparty does not borrow and deliver.
Neither the Securities and Exchange Commission (the “SEC”) nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.
The underwriters expect that the shares of our common stock will be delivered against payment on or about November , 2023.
Joint Book-Running Managers
| | |
Wells Fargo Securities | | Morgan Stanley |
The date of this prospectus supplement is November , 2023.